Severe Hypersensitivity Reactions to Biological Drugs in Children with Rheumatic Diseases

Rheumatoid Arthritis

Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice

Clin Exp Rheumatol.

Leon L, Gomez A, Vadillo C, Pato E, Rodriguez-Rodriguez L, Jover JA, Abasolo L

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Semin Arthritis Rheum.

Michelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, Erra A, Serrat M, Espartal E, Antón S, Añez GA, Caparrós-Ruiz R, Pluma A, Trallero-Araguás E, Barceló-Bru M, Almirall M, De Agustín JJ, Segura JL, Julià A, Marsal S

doi: 10.1016/j.semarthrit.

Allergic Diseases

A Multicenter retrospective study on hypersensitivity reactions to Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in children: a report from the European Network on Drug Allergy (ENDA) group

J Allergy Clin Immunol Pract.

Francesca M, Marina AM, Natalia BL, Eva G, Francesco G, Lucrezia S, Marcel M B, Vladimir T, Rocco L V, Jean-Christoph C

doi: 10.1016/j.jaip.2019.10.049.

Juvenile Idiopathic Arthritis

Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database

Joint Bone Spine.

Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-Paut I, Belot A, Hofer M

doi: 10.1016/j.jbspin.2018.08.003.

Further Publications Immunology

Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity

Immunol Allergy Clin North Am

Macy E

doi: 10.1016/j.iac.2020.06.003

The use of biologics in pregnant patients with rheumatic disease.

Expert Rev Clin Pharmacol.

Østensen M

doi: 10.1080/17512433.2017.

Rheumatoid Arthritis

Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs

Arthritis Rheumatol.

Dagliati A, Plant D, Nair N, Jani M, Amico B, Peek N, Morgan AW, Isaacs J, Wilson AG, Hyrich KL, Geifman N, Barton A, BRAGGSS.

doi: 10.1002/art.41379.

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

doi: 10.1016/S0140-

Rheumatoid Arthritis

Combination therapy with biologic agents in rheumatic diseases: current and future prospects

Ther Adv Musculoskelet Dis.

Inui K, Koike T

doi: 10.1177/

Related content

Severe adverse drug reactions to biological disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis in clinical practice

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

A Multicenter retrospective study on hypersensitivity reactions to Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in children: a report from the European Network on Drug Allergy (ENDA) group

Safety of biological agents in paediatric rheumatic diseases: a real-life multicenter retrospective study using the JIRcohorte database

Immune-Related Adverse Drug Reactions and Immunologically Mediated Drug Hypersensitivity

The use of biologics in pregnant patients with rheumatic disease.

Latent class trajectory modelling of 2-components-DAS28 identifies multiple rheumatoid arthritis phenotypes of response to biologic disease modifying anti-rheumatic drugs

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Combination therapy with biologic agents in rheumatic diseases: current and future prospects